Compare AbCellera Biologics Inc (ABCL) vs United States Oil ETF (USO) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

USO (United States Oil Fund) trades at $104.35, showing modest daily gains of 0.36% amid heightened geopolitical tensions in the Middle East. Technical indicators signal a bearish trend with moving averages showing strong sell signals, though oscillators remain neutral. The fund's price action reflects direct exposure to crude oil volatility, with recent U.S. military strikes against Iran and attacks in the Strait of Hormuz driving supply disruption fears and price increases.

The outlook remains heavily dependent on geopolitical developments and oil supply dynamics. While recent Middle East tensions provide upward price pressure, risks include potential supply increases from Gulf producers and weak demand signals that could limit sustained recovery. The fund offers direct commodity exposure but faces contango risks and tracking error inherent to futures-based ETFs.